Geetanjali Saini
Overview
Explore the profile of Geetanjali Saini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
230
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bhattarai S, Rupji M, Chao H, Xu Q, Saini G, Rida P, et al.
BJC Rep
. 2024 Nov;
2(1):87.
PMID: 39537757
Background: Ki67 index (KI) and mitotic index (MI) are proliferation markers with established prognostic value in breast carcinomas. While KI is evaluated immunohistochemically and reported as a percentage, MI is...
2.
Sharma A, Singh S, Saini G, Sharma S, Singh B, Choudhary D
Ann Pharm Fr
. 2024 Jul;
82(6):1103-1117.
PMID: 39002854
Objective: The traditional drug delivery system is not much effective when treating chronopathological diseases like arthritis. Consequently, there is a gap in the market for a delivery system that can...
3.
Singh J, Saini G, Tiwari G, Singh B
Pharm Nanotechnol
. 2024 May;
PMID: 38757163
Transdermal drug delivery is an attractive and patient-friendly route for administering therapeutic agents. However, the skin's natural barrier, the stratum corneum, restricts the passage of many drugs, limiting their effectiveness....
4.
Fisher T, Saini G, Rekha T, Krishnamurthy J, Bhattarai S, Callagy G, et al.
Breast Cancer Res
. 2024 Jan;
26(1):12.
PMID: 38238771
Background: Pathological complete response (pCR) is associated with favorable prognosis in patients with triple-negative breast cancer (TNBC). However, only 30-40% of TNBC patients treated with neoadjuvant chemotherapy (NAC) show pCR,...
5.
Bhattarai S, Saini G, Li H, Seth G, Fisher T, Janssen E, et al.
Diagnostics (Basel)
. 2024 Jan;
14(1).
PMID: 38201383
Background: Neoadjuvant chemotherapy (NAC) is the standard treatment for early-stage triple negative breast cancer (TNBC). The primary endpoint of NAC is a pathological complete response (pCR). NAC results in pCR...
6.
Fisher T, Saini G, Ts R, Krishnamurthy J, Bhattarai S, Callagy G, et al.
Res Sq
. 2023 Aug;
PMID: 37645881
Background: Pathological complete response (pCR) is associated with favorable prognosis in patients with triple-negative breast cancer (TNBC). However, only 30-40% of TNBC patients treated with neoadjuvant chemotherapy (NAC) show pCR,...
7.
Awan S, Saini G, Gogineni K, Luningham J, Collin L, Bhattarai S, et al.
Cancer Med
. 2023 Jul;
12(16):17331-17339.
PMID: 37439033
Background: Little is known regarding the association between insurance status and treatment delays in women with breast cancer and whether this association varies by neighborhood socioeconomic deprivation status. Methods: In...
8.
Bhattarai S, Saini G, Li H, Duanmu H, Seth G, Fisher T, et al.
bioRxiv
. 2023 May;
PMID: 37131688
Background: Neoadjuvant chemotherapy (NAC) is the standard treatment for early-stage triple negative breast cancer (TNBC). The primary endpoint of NAC is a pathological complete response (pCR). NAC results in pCR...
9.
Luningham J, Seth G, Saini G, Bhattarai S, Awan S, Collin L, et al.
JAMA Netw Open
. 2022 Oct;
5(10):e2238183.
PMID: 36306134
Importance: Increasing evidence suggests that low socioeconomic status and geographic residence in disadvantaged neighborhoods contribute to disparities in breast cancer outcomes. However, little epidemiological research has sought to better understand...
10.
Saini G, Gogineni K, Kittles R, Aneja R
Breast Cancer Res Treat
. 2021 Jun;
187(3):605-611.
PMID: 34080093
Precision (or personalized) medicine holds great promise in the treatment of breast cancer. The success of personalized medicine is contingent upon inclusivity and representation for minority groups in clinical trials....